v3.25.2
Segments - Schedule of Reportable Segment Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]        
Chronic cough in IPF clinical trial expense $ 3,039 $ 3,721 $ 5,921 $ 6,524
Refractory chronic cough clinical trial expense 434 1,655 1,252 2,606
Clinical trial material 330 798 564 1,337
Other clinical trials and studies [1] 1,269 1,131 1,317 3,162
Other clinical development expenses [2] 1,861 850 3,279 1,752
Employee compensation (excluding stock compensation expense) 2,818 2,249 5,775 4,432
Stock-based compensation expense 1,384 1,127 2,592 1,850
Other segment items [3] 2,573 1,756 4,473 3,524
Interest income, net (1,407) (935) (2,532) (1,933)
Net loss $ 12,301 $ 12,352 $ 22,641 $ 23,254
[1] Includes expense related to the Company’s drug-drug interaction study, human abuse potential study, Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with IPF, and Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis.
[2] Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.
[3] Includes general administrative expense, interest expense, net, other (expense) income, net and income tax benefit.